Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

<h3>Background</h3> We assessed the efficacy and safety of avelumab, an anti-programmed death ligand 1 (PD-L1) antibody, in patients with previously treated metastatic adrenocortical carcinoma (mACC). <h3>Methods</h3> In this phase 1b expansion cohort, patients with mACC and...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Christophe Le Tourneau, Christopher Hoimes, Corrine Zarwan, Deborah Jean Lee Wong, Sebastian Bauer, Rainer Claus, Martin Wermke, Hariharan Subramanian, Anja von Heydebreck, Vijay Kasturi, Vikram K. Chand, James L. Gulley
Format: Artigo
Jezik:angleščina
Izdano: 2018
Online dostop:https://doi.org/10.1186/s40425-018-0424-9
https://jitc.bmj.com/content/jitc/6/1/111.full.pdf
Oznake: Označite
Brez oznak, prvi označite!

Internet

https://doi.org/10.1186/s40425-018-0424-9
https://jitc.bmj.com/content/jitc/6/1/111.full.pdf

Podobne knjige/članki